Quantitative Concept
Veru Survey Highlights Muscle Loss Concerns Among GLP-1 Users as Lean Mass-Preserving Drug Advances
Veru; GLP-1 receptor agonists; muscle loss; enobosarm; lean mass; obesity; survey; older adults; high-protein diet
Recent Developments in Building Measurable Patient Support Programs (2025)
patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care
FDA Commissioner Makary Proposes Fast-Track Drug Review Vouchers Tied to Lower US Prices, Without Detailing Criteria
FDA; Makary; national priority review vouchers; drug pricing; fast-track approval; price parity; pilot program
Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer
Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)
Nimble radiopharma biotech Actithera secures $75M Series A to enter the clinic
Actithera; radiopharma; Series A; biotech funding; clinic entry; Andreas Goutopoulos; startup financing
FDA Acting CDER Head Jacqueline Corrigan-Curay to Retire Amid Leadership Turnover
FDA; Jacqueline Corrigan-Curay; CDER; retirement; leadership turnover; drug regulation; agency departures
Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns
Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor
Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study
Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial
Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial
Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor
Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising
Trump administration; DTC drug advertising; pharmaceutical regulation; drug pricing; executive order; health policy; pharma marketing